-- Israel Stocks: Amot, Enlight, IDB Holding, Clal, Teva, Mellanox
-- B y   S h o s h a n n a   S o l o m o n
-- 2012-05-20T14:12:09Z
-- http://www.bloomberg.com/news/2012-05-20/israel-stocks-amot-enlight-idb-holding-clal-industries-teva.html
Israel ’s  TA-25 index  dropped to the
lowest level since February 28, retreating 0.8 percent to
1,072.77 at 4:30 p.m. in  Tel Aviv . Investors traded about 835
million shekels ($218 million) of shares and convertible
securities, according to bourse data.  The following stocks rose or fell today. Symbols are in
parentheses.  Amot Investments Ltd. (AMOT)   advanced the most since
April 17, gaining 1.3 percent to 9.07 shekels. The real estate
developer said first-quarter net income increased to 44.9
million shekels ($12 million) from 36.5 million shekels a year
earlier.  Enlight Renewable Energy Ltd. (ENLT)   advanced 2.6
percent, the most since May 14, to 0.237 shekel. The developer
of photo-voltaic systems secured bank funding for two projects.  IDB Holding Corp. (IDBH)   added 1.7 percent, the most
since May 8, to 19 shekels. The holding company said its IDB
Development Corp. unit agreed to sell a 49.9 percent stake of
 Clal Industries and Investments Ltd.  (CII IT). Clal Industries
advanced 3.8 percent, the most since March 1.  Discount
Investment Corp. (DISI)  , a unit of IDB Development, dropped
1.1 percent to 8.80 shekels.  Mellanox Technologies Ltd. (MLNX)   dropped 5.8 percent,
the biggest slump since Nov. 20, to 209.50 shekels, or the
equivalent of $54.79. The shares of the developer of technology
used to transfer and store data quickly lost 6.8 percent in the
last two days of trading in  New York  and closed at $54.12 on May
18.  Reit 1 Ltd. (RIT1)  (RIT1 IT) advanced 1.7 percent to 6.813
shekels. Shmuel Sayad, chief executive officer, said in an
interview a slowdown in Israeli economic growth would give the
country’s first real-estate investment trust a chance to invest
in more properties at better prices.  Teva Pharmaceutical Industries Ltd. (TEVA)   dropped 3.6
percent, the biggest decline since Oct. 4, to 150.40 shekels, or
the equivalent of $39.33. The shares of the world’s largest
generic drugmaker in New York fell 7 percent last week to close
at $38.90 on May 18.  To contact the reporter on this story:
Shoshanna Solomon in Tel Aviv at 
 ssolomon22@bloomberg.net   To contact the editor responsible for this story:
Claudia Maedler at 
 cmaedler@bloomberg.net  